Shin et al. (27) reported that, after treatment with Ceranib-2 or MP-A08, IL-17A, IL-17F, and TNF-α levels were significantly decreased (p<0.05) compared with those in IMQ-induced skin inflammation. This evidence concerns the gene IL17F and dermatitis.